Cargando…
T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
Autores principales: | Gallamini, Andrea, Picardi, Marco, Filonenko, Kateryna, Gotti, Manuel, Céspedes, Javier Núñez, Rossi, Andrea, Domingo-Domènech, Eva, Giza, Agnieszka, Sorasio, Roberto, Trentin, Livio, Oteiro, Mariana Bastos, Paszkiewicz-Kozik, Ewa, Sanz, Ramon García, Patti, Caterina, Chauvie, Stephane, Bergesio, Fabrizio, Guerra, Luca, Rambaldi, Alessandro, Balari, Ana Sureda, Zaucha, Jan Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642047/ http://dx.doi.org/10.1097/01.HS9.0000890652.56016.97 |
Ejemplares similares
-
P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022) -
T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022) -
P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022) -
P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022) -
T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)